Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
The Leukemia & Lymphoma Society
Headquarters: White Plains, NY, United States of America
Website: http://www.lls.org
Year Founded: 1949
Status: Non-biopharma
Biopharma related deals can be found by searching the organization's name in the Deals Module.
BioCentury | Mar 19, 2025
Emerging Company Profile
Trio: Introducing two new types of dual-targeting antibodies for cancer
San Francisco Bay Area biotech has two antibody platforms designed to improve on the potency and safety of bispecifics
BioCentury | Mar 5, 2025
Deals
Chimerix’s alignment with FDA on submission drives $935M takeout by Jazz
Building in oncology, Jazz obtains targeted glioma therapy under FDA review
BioCentury | Mar 1, 2025
Data Byte
EMA’s CHMP reaffirms its decision to back Leqembi for Alzheimer’s
Regeneron’s bispecific, Krystal’s gene therapy, and 16 label extensions also among positive opinions issued at committee’s February meeting
BioCentury | Feb 28, 2025
Product Development
Caribou: Solving the allogeneic problem with CRISPR
Caribou selected a de-risked target and modality to take on multiplexed editing
BioCentury | Feb 25, 2025
Product Development
Indication selection: Lessons learned from the CRISPR-Cas9 story
Founding CEOs of gene editing companies discuss their pipeline strategies and lessons learned
BioCentury | Feb 18, 2025
Product Development
Remaking Roche
How the once-dominant cancer company has overhauled its strategy for long-term growth
BioCentury | Jan 25, 2025
Management Tracks
Sara Brenner moves from CDHR to acting FDA commissioner
Plus: Northcott to lead commercial at Nurix, Bach joins Limani Partners and updates from the National MS Society, Octopus and Neurocrine
BioCentury | Jan 24, 2025
Finance
Ascentage lists on NASDAQ as Odyssey, Sionna, Aardvark plot IPOs
In BioCentury’s Finance Report, two more companies plan Hong Kong listings; Disc Medicine, Arctic raise cash
BioCentury | Jan 18, 2025
Politics, Policy & Law
FTC calls out PBM price gouging of specialty generic drugs
Report says Big 3 PBMs mark up 22% of specialty generics by more than 1,000%
Items per page:
1 - 10 of 7664